Earnings call transcript: Pluxee Q3 2026 revenue slows as Brazil reform bites

Pluxee reported Q3 revenue of EUR 312m, down 3.3% organically (reported +0.9%), as Brazil’s PAT meal-benefit reform initially reduced the group take-up rate by ~50 bps; however, Q3 business volume issued (BVI) rose 9.4% organically to EUR 6.6bn. Over nine months, revenue grew 2.7% organically to EUR 967m and management reiterated fiscal 2026 guidance for stable organic revenue and slight EBITDA margin expansion, while warning the Brazil PAT impact should roughly double in Q4. Float revenue grew to EUR 42m in Q3 (+2.8% organic) and EUR 124m over nine months (+4.5% organic), and management highlighted FX effects as reported growth drivers. Shares were largely unchanged on the day, suggesting the regulatory headwind was at least partly priced in, with continued uncertainty around the reform’s longer-term revenue/cash-flow impact.

Analysis

Brazil is the real mechanism here: the reform is not killing demand, it is compressing the toll booth. That means the market is likely overreacting if it is extrapolating topline pressure into a permanent franchise impairment, because volume growth remains the cleaner signal for forward earnings power. The key question is not whether revenue slows over the next 1-2 quarters; it is whether the new operating structure preserves enough take-rate and float economics to re-accelerate cash generation once the transition is absorbed.

Near term, the setup is still ugly. Q4 and early FY27 are the likely trough because the full regulatory drag hits before offsetting benefits from Europe’s cap changes and the U.K./U.S. restructuring can scale. Smaller Brazil-focused competitors should feel the squeeze harder than Pluxee because they have less balance-sheet flexibility, weaker client breadth, and less ability to subsidize transition costs; that raises medium-term consolidation odds, but not quickly enough to matter for the next print.

Contrarian view: consensus may be missing the asymmetry between revenue and economics. If merchants keep using the express reimbursement option, float and cash flow could be less damaged than feared; if they do not, the business takes a bigger operating-revenue hit but preserves more balance-sheet cash. The thesis breaks if BVI decelerates materially, if Q4 revenue falls worse than management’s implied path, or if Brazil legal/regulatory uncertainty extends beyond the current fiscal year without a visible merchant adoption offset.

Key Decisions for Investors

• PLUX: stay sidelined for now; do not add ahead of Q4 because the next two quarters are the highest-risk window for headline revenue downgrades and the stock can stay cheap longer than the catalyst path.
• PLUX: consider a tactical short or put-spread into the Q4 update only if the name rallies back toward the pre-result range; cover immediately if management shows take-rate stabilization or if organic decline proves materially less severe than the guided step-up in Brazil.
• PLUX: for a longer-term position, wait for evidence in FY27 that open-loop adoption and public-sector prepaid migration are improving cash conversion; that is the cleaner entry point for a 6-12 month long.
• Watch item: if quarterly BVI stays near high-single/low-double-digit growth while revenue keeps slipping, the market may be creating a valuation gap worth buying on the first sign of Brazil merchant normalization.